Therapy of Type 2 Diabetes

Rüdiger Landgraf; Jens Aberle; Andreas L. Birkenfeld; Baptist Gallwitz; Monika Kellerer; Harald Klein; Dirk Müller-Wieland; Michael A. Nauck; Tobias Wiesner; Erhard Siegel

doi:10.1055/a-1624-3449

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2022; 130(S 01): S80-S112
DOI: 10.1055/a-1624-3449

German Diabetes Association: Clinical Practice Guidelines

Therapy of Type 2 Diabetes

Authors

Rüdiger Landgraf

¹German Diabetes Foundation, Munich, Germany
Jens Aberle

²Division of Endocrinology and Diabetology, University Obesity Centre Hamburg, University Hospital Hamburg-Eppendorf, Germany
Andreas L. Birkenfeld

³German Centre for Diabetes Research (DZD e. V.), Neuherberg, Germany
Baptist Gallwitz

⁴Department of Internal Medicine IV, Diabetology, Endocrinology, Nephrology, University Hospital Tübingen, Germany
Monika Kellerer

⁵Department of Internal Medicine I, Marienhospital, Stuttgart, Germany
Harald Klein

⁶Department of Internal Medicine I, University Hospital Bergmannsheil, Bochum, Germany
Dirk Müller-Wieland

⁷Department of Internal Medicine I, University Hospital RWTH, Aachen, Germany
Michael A. Nauck

⁸Diabetes Centre Bochum-Hattingen, St.-Josef-Hospital, Ruhr-University, Bochum, Germany
Tobias Wiesner

⁹MVZ Metabolic Medicine Leipzig, Leipzig, Germany
Erhard Siegel

¹⁰Department of Internal Medicine – Gastroenterology, Diabetology/Endocrinology and Nutritional Medicine, St. Josefkrankenhaus Heidelberg GmbH, Heidelberg, Germany

Abstract

Full Text

References

References
1 Nationale VersorgungsLeitlinien. NVL-2-Diabetes – Teilpublikation, 2. Auflage: www.leitlinien.de/themen/diabetes
2 Alberti KGMM, Eckel RH, Grundy SM. et al. Harmonizing the Metabolic Syndrome. Circulation 2009; 120: 1640-1645
3 Elwyn G, Vermunt NPCA. Goal-based shared decision-making: developing an integrated model. J Patient Exp 2019; 1-9
4 Wang R, Song Y, Yan Y. et al. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis. Atherosclerosis 2016; 254: 193-199
5 Parhofer KG, Birkenfeld AL, Krone W. et al. Lipidtherapie bei Patienten mit Diabetes mellitus. Diabetologie 2020; 15: S160-S165
6 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
7 The Task Force for the management of arterial hypertension of the European Society of cardiology (ESC) and the European Society of Hypertension (ESH). 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104
8 Heinemann L, Kaiser P, Freckmann G. et al. HbA1c-Messung in Deutschland: Ist die Qualität ausreichend für Verlaufskontrolle und Diagnose?. Diabetologie 2018; 13: 46-53
9 Landgraf R, Nauck M, Freckmann G. et al. Fallstricke bei der Diabetesdiagnostik: Wird zu lax mit Laborwerten umgegangen?. Dtsch Med Wochenschr 2018; 143: 1549-1555
10 Nauck M, Gerdes C, Petersmann A. et al. Definition, Klassifikation und Diagnostik des Diabetes mellitus. Update 2020. Diabetologie 2020; 15: S9-S17
11 Landgraf R. HbA1c in der Diabetesdiagnostik. Der Goldstandard?. Diabetes aktuell 2021; 19: 22-29
12 Ahlqvist E, Storm P, Käräjämäki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6: 361-369
13 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
14 Dennis JM, Shields BM, Henley WE. et al. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 2019; 7: 442-451
15 Zhang Y, Pan XF, Chen J. et al. Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Diabetologia 2020; 63: 21-3316
16 Nationale VersorgungsLeitlinie (NVL) Diabetes – Strukturierte Schulungsprogramme 2018 www.leitlinien.de/nvl/diabetes/schulungsprogramme
17 Forouhi NG, Misra A, Mohan V. et al. Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ 2018; 361: k2234
18 Serra-Majem L, Román-Viñas B, Sanchez-Villegas A. et al. Benefits of the Mediterranean diet: Epidemiological and molecular aspects. Mol Aspects Med 2019; 67: 1-55
19 Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol 2019; 7: 726-736
20 Evert AB, Dennison M, Gardner CD. et al. Nutrition therapy for adults with Diabetes or prediabetes: a consensus report. Diabetes Care 2019; 42: 731-754
21 Hauner H. Evidenz in der Ernährungstherapie des Diabetes mellitus. Der Diabetologe 2021; 17: 687-696
22 Chester B, Babu JR, Greene MW. et al. The effects of popular diets on type 2 diabetes management. Diabetes Metab Res Rev 2019; 35: e3188
23 Kempf K, Altpeter B, Berger J. et al. Efficacy of the telemedical lifestyle intervention program TeLiPro in advanced stages of type 2 diabetes: A randomized controlled trial. Diabetes Care 2017; 40: 863-871
24 Lean MEJ, Leslie WS, Barnes AC. et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomized trial. Lancet Diabetes Endocrinol 2019; 7: 344-355
25 Adipositas – Prävention und Therapie. AWMF-Register Nr. 050-001.
26 Aberle J, Lautenbach A, Meyhöfer S. et al. Adipositas und Diabetes. Diabetologe 2021; 16: S290-S298
27 Yang D, Yang Y, Li Y. et al. Physical exercise as therapy for type 2 diabetes mellitus: from mechanism to orientation. Ann Nutr Metab 2019; 74: 313-321
28 Tarp J, Støle AP, Blond K. et al. Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and metaanalysis. Diabetologia 2019; 62: 1129-1142
29 Liu Y, Ye W, Chen Q. et al. Resistance exercise intensity is correlated with attenuation of HbA1c and insulin in patients with type 2 diabetes: A systematic review and meta-analysis. Int J Environ Res Public Health 2019; 16: 140
30 Esefeld K, Kress S, Behrens M. et al. Diabetes, Sport und Bewegung. Diabetologe 2021; 16: S299-S307
31 Piercy KL, Richard P, Troiano RP. et al. The physical activity guidelines for Americans. JAMA 2018; 320: 2020-2028
32 Jabardo-Camprubí G, Donat-Roca R, Sitjà-Rabert M. et al. Drop-out ratio between moderate to high-intensity physical exercise treatment by patients with, or at risk of, type 2 diabetes mellitus: A systematic review and meta-analysis. Physiol Behav 2020; 215: 112786
33 Kar D, Gillies C, Nath M. et al. Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetologica 2019; 56: 839-850
34 Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung. S3-Leitlinie Langversion AWMF-Register Nr. 076-006
35 Tabakatlas Deutschland 2020 www.dkfz.de/de/tabakkontrolle/download/Publikationen/sonstVeroeffentlichungen/Tabakatlas-Deutschland- 2020_dp.pdf Seiten 38–39 und 110–111
36 Fleming GA, Petrie JR, Bergenstal RM. et al. Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care 2020; 43: 250-260
37 Khunti K, Gomes MB, Pocock S. et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes Obes Metab 2018; 20: 427-437
38 Matthews DR, Paldánius PM, Proot P. VERIFY study group et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 2019; 394: 1519-1529
39 Gough SC, Bode B, Woo V. et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabet Endocrinol 2014; 2: 885-893
40 Diamant M, Nauck MA, Shaginian R. et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014; 37: 2763-2773
41 Ahmann A, Rodbard HW, Rosenstock J. et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo controlled trial. Diabetes Obes Metab 2015; 17: 1056-1064
42 Montvida O, Klein K, Kumar S. et al. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Diabetes Obes Metab 2017; 19: 108-117
43 Billings LK, Doshi A, Gouet D. et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The DUAL VII randomized clinical trial. Diabetes Care 2018; 41: 1009-1016
44 Parhofer KG. Lipidtherapie. Diabetologe 2021; 16: S312-S317
45 Mengden T, Weisser B. Therapieüberwachung bei arterieller Hypertonie. Dtsch Ärztebl 2021; 118: 473-478
46 Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter 2018 www.leitlinien.de/nvl/diabetes/nierenerkrankungen
47 ESC/ESH Guidelines 2018. Management der arteriellen Hypertonie www.dgk.de
48 American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2021. Diabetes Care 2021; 44: S125-S150
49 The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103-2116
50 Banegas JR, Ruilope LM, de la Sierra A. et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl JMed 2018; 378: 1509-1520
51 Lawall H, Huppert P, Rümenapf G. et al. Periphere arterielle Verschlusskrankheit (PAVK), Diagnostik, Therapie und Nachsorge. AWMF-Register Nr. 065–003 2015
52 Nationale VersorgungsLeitlinie Neuropathie bei Diabetes im Erwachsenenalter. 2016 www.leitlinien.de/mdb/downloads/nvl/ diabetesmellitus/dm-neuropathie
53 Nationale VersorgungsLeitlinie Prävention und Therapie von Netzhautkomplikationen bei Diabetes. 2016 www.leitlinien.de/nvl/ html/netz.hautkomplikationen
54 Nationale VersorgungsLeitlinie (NVL) Typ-2-Diabetes Präventions-und Behandlungsstrategien für Fußkomplikationen. 2018 www.leitlinien. de/nvl/diabetes/fusskomplikationen
55 Roeb E, Steffen HM, Bantel H. et al. S2k-Leitlinie: Nicht-alkoholische Fettlebererkrankungen. AWMF-Register Nr. 021–025 2015
56 Wang R, Song Y, Yan Y. et al. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis. Atherosclerosis 2016; 254: 193-199
57 Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz. 2020 https://www.leitlinien.de/nvl/html/nvl-chronische-herzinsuffizienz
58 Nationale VersorgungsLeitlinie Chronische Koronare Herzerkrankung (KHK). 2019 https://www.leitlinien.de/mdb/downloads/nvl/khk/, www.leitlinien.de/nvl/html/nvl-chronische-khk
59 Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter. 2018 www.leitlinien.de/nvl/diabetes/ nierenerkrankungen
60 The Look AHEAD Research Group. Cardiovascular effects ofintensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154
61 Unick JL, Gaussoin SA, Hill JO. et al. Objectively assessed physical activity and weight loss maintenance among individuals enrolled in a lifestyle intervention. Obesity (Silver Spring) 2017; 25: 1903-1909
62 The Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fitness with longterm cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol 2016; 4: 913-921
63 Gregg EW, Lin J, Bardenheier B. et al. Impact of Intensive Lifestyle Intervention on Disability-Free Life Expectancy: The Look AHEADStudy. Diabetes Care 2018; 41: 1040-1048
64 Chao AM, Wadden TA, Berkowitz RI. Look AHEAD Research Group et al. Weight change 2 years after termination of the intensive lifestyle intervention in the Look AHEAD Study. Obesity 2020; 28: 893-890
65 Yang D, Yang Y, Li Y. et al. Physical exercise as therapy for type 2 diabetes mellitus: from mechanism to orientation. Ann Nutr Metab 2019; 74: 313-321
66 Tarp J, Støle AP, Blond K. et al. Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and metaanalysis. Diabetologia 2019; 62: 1129-1142
67 Liu Y, Ye W, Chen Q. et al. Resistance exercise intensity is correlated with attenuation of HbA1c and insulin in patients with type 2 diabetes: A systematic review and meta-analysis. Int J Environ Res Public Health 2019; 16: E140
68 www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/ DE/RV_STP/m-r/metformin.html
69 Lazarus B, Wu A, Shin JI. et al. Association of metformin use with risk of lactic acidosis across the range of kidney function. A communitybased cohort study. JAMA Intern Med 2018; 178: 903-910
70 Griffin SJ, Leaver JK, Irving GJ. et al. Impact of metformin on cardiovascular disease: a meta-analysis of randomized trails among people with type 2 diabetes. Diabetologia 2017; 60: 1620-1629
71 Palmer SC, Mavridis D, Nicolucci A. et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA 2016; 316: 313-324
72 Madsen KS, Kähler P, Kähler LKA. et al. Metformin and second- or third generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2019; 4: CD012 368
73 Sattar N, McGuire DK. Prevention of CV outcomes in antihyperglycemic drug-naive patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin. Eur Heart J 2021; 42: 2574-2576
74 Rena G, Mordi IR, Lang CC. Metformin: still the sweet spot for CV protection in diabetes?. Curr Opin Pharmacol 2020; 54: 202-208
75 Mallik R, Chowdhury TA. Metformin in cancer. Diabetes Res Clin Pract 2018; 143: 409-419
76 Thakur S, Daley B, Klubo-Gwiezdzinska J. The role of the antidiabetic drug metformin in the treatment of endocrine tumors. J Mol Endocrinol 2019; 63: R17-R35
77 De A, Kuppusamy G. Metformin in breast cancer: preclinical and clinical evidence. Curr Probl Cancer 2020; 44: 100488
78 Rahmani J, Manzari N, Thompson J. et al. The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials. Clin Transl Oncol 2020; 22: 37-49
79 Fong W, To KKW. Drug repurposing to overcome resistance to various therapies for colorectal cancer. Cell Mol Life Sci 2019; 76: 3383-3406
80 Aljofan M, Riethmacher D. Anticancer activity of metformin: a systematic review of the literature. Future Sci OA 2019; 5: FSO410
81 Feng Z, Zhou X, Liu N. et al. Metformin use and prostate cancer risk: A meta-analysis of cohort studies. Medicine (Baltimore) 2019; 98: e14 955
82 Park YMM, Bookwalter DB, O’Brien KM. et al. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Ann Oncol 2021; 32: 351-359
83 Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. Front Endocrinol 2020; 11: 191
84 Khunti K, Knighton P, Zaccardi F. et al. Prescription of glucoselowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol 2021; 9: 293-303
85 Wargny M, Potier L, Gourdy P. et al. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia 2021; 64: 778-794
86 Kow CS, Hasan SS. Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis. J Med Virol 2021; 93: 695-697
87 Lim S, Bae JH, Kwon H-S, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 2021; 17: 11-30
88 Bornstein SR, Rubino F, Khunti K. et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020; 8: 546-50
89 Oshima M, Jun M, Ohkuma T. et al. The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. Diabetologia 2019; 62: 1988-1997
90 The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
91 Rosenstock J, Kahn SE, Johansen OE. on behalf of the CAROLINA. Investigators et al. Effect of linagliptin vs. glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA randomized clinical trial. JAMA 2019; 322: 1155-1166
92 Rados DV, Pinto LC, Remonti LR. et al. The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 2016; 13: e1002 091
93 Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: A methodological meta-regression analysis of the observational studies. Diabetes Care 2017; 40: 706-714
94 Bain S, Druyts E, Balijepalli C. et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab 2017; 19: 329-335
95 Zhuang XD, He X, Yang DY. et al. Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166 371 participants from170 randomized controlled trials. Cardiovasc Diabetol 2018; 17: 79
96 Powell WR, Christiansen CL, Miller DR. Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments. Diabetes Ther 2018; 9: 1431-1440
97 Simpson SH, Lee J, Choi S. et al. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 2015; 3: 43-51
98 Hemmingsen B, Schroll JB, Lund SS. et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; 4: CD009 008
99 Hemmingsen B, Schroll JB, Jorn Wetterslev J. et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochranesystematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2014; 2: E162-E175
100 Vaccaro O, Masulli M, Nicolucci M. et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomized, multicenter trial. Lancet Diabetes Endocrinol 2017; 5: 887-897
101 Ogundipe O, Mazidi M, Chin KL. et al. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. Acta Diabetologica 2021; 58: 39-46
102 Chen K, Kang D, Yu M. et al. Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A metaanalysis of long-term randomized controlled trials. Diabetes Obes Metab 2018; 20: 1029-1033
103 Patorno E, Schneeweiss S, Gopalakrishnan C. et al. Using realworld data to predict findings of an ongoing phase IV cardiovascular outcome trial: Cardiovascular safety of linagliptin versus glimepiride. Diabetes Care 2019; 42: 2204-2210
104 Scirica BM, Bhatt DL, Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326
105 White WB, Cannon CP, Heller SR. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335
106 Green JB, Bethel MA, Armstrong PW. et al. TECOS Study Group Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-242
107 Rosenstock J, Perkovic V, Johansen OE. et al. Effect of linagliptin vs placebo on major cardiovasculareEvents in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA Randomized Clinical Trial. JAMA 2019; 321: 69-79
108 Perkovic V, Toto R, Cooper ME. et al. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care 2020; 43: 1803-1812
109 Monami M, Ahrén B, Dicembrini I. et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: ameta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15: 112-120
110 Xu S, Zhang X, Tang L. et al. Cardiovascular effects of dipeptidylpeptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review. Postgrad Med 2017; 129: 205-215
111 Zheng SL, Roddick AJ, Aghar-Jaffar R. et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA 2018; 319: 1580-1591
112 Ling J, Cheng P, Ge L. et al. The efficacy and safety of dipeptidyl peptidase- 4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetologica 2019; 56: 249-272
113 Li L, Li S, Deng K. et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMJ 2016; 352: i610
114 GuoWQ Li L, Su Q. et al. Effect of dipeptidylpeptidase-4 inhibitors on heart failure: A network meta-analysis. Value Health 2017; 20: 1427-1430
115 Nauck MA, Meier JJ, Cavender MA. et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 2017; 136: 849-870
116 Yan Xie Y, Bowe B, Gibson AK. et al. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases. Diabetes Care 2020; 43: 2859-2869
117 Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 2019; 150: 8-16
118 Dougherty J, Guirguis E, Thornby KA. et al. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Annals of Pharmacotherapy 2021; 55: 65-79
119 Koufakis T, Mustafa OG, Zebekakis P, Kotsa K. Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close T. Diabet Med 2020; 37: 1418-1426
120 Du H, Wang DW, Chen C. The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients. J Cell Mol Med 2020; 24: 10 274-10 278
121 Bonora BM, Avogaro A, Fadini GP. Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. J Endocrinol Invest 2021; 44: 1379-1386
122 Tkáč I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017; 40: 284-286
123 Pinto LC, Rados DV, Barkann SS. et al. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis. Sci Rep 2018; 8: 782
124 Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid. Front Immunol 2019; 10: 1238
125 Overbeek JA, Bakker M, van der Heijden AAWA. et al. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes Metab Res Rev 2018; 34: e3004
126 Abrahami D, Douros A, Yin H. et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018; 360: k872
127 Li G, Crowley MJ, Tang H. et al. Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease among patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetes Care 2019; 42: e119-e121
128 Storgaard H, Gluud LL, Bennett C. et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS One 2016; 11: e0166 125
129 Monami M, Liistro F, Scatena A. et al. Short andmedium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A metaanalysis of randomized clinical trials. Diabetes Obes Metab 2018; 20: 1213-1222
130 Usman MS, Siddiqi TJ, Memon MM. et al. Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol 2018; 25: 495-502
131 Mishriky BM, Tanenberg RJ, Sewell KA. et al. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab 2018; 44: 112-120
132 Seidu S, Kunutsor SK, Cos X. et al. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Prim Care Diabetes 2018; 12: 265-283
133 Rådholm K, Wu JH, Wong MG. et al. Effects of sodium-glucose cotransporter- 2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review. Diabetes Res Clin Pract 2018; 140: 118-128
134 Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 2019; 150: 8-16
135 Zheng SL, Roddick AJ, Aghar-Jaffar R. et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: A Systematic Review and Meta-analysis. JAMA 2018; 319: 1580-1591
136 Aronson R, Frias J, Goldman A. et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DMdespite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab 2018; 20: 1453-1460
137 Hollander P, Hill J, Johnson J. et al. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on Metformin. Curr Med Res Opin 2019; 35: 1335-1343
138 Zelniker TA, Wiviott SD, Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 201; 393: 31–39
139 Puckrin R, Saltiel MP, Reynier P. et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 2018; 55: 503-514
140 Lega IC, Bronskill SE, Campitelli MA. et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes Obes Metab 2019; 21: 2394-2404
141 Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium glucose co-transporter-2 inhibitors. Diabetes Obes Metab 2019; 21: 434-438
142 Lega IC, Bronskill SE, Campitelli MA. et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes Obes Metab 2019; 21: 2394-2404
143 McGovern AP, Hogg M, Shields BM. et al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diab Res Care 2020; 8: e001238
144 Yang JY, Wang T, Pate V. et al. Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene. BMJ Open Diab Res Care 2020; 8: e000985
145 Silverii GA, Dicembrini I, Monami M. et al. Fournier’s gangrene and sodium-glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020; 22: 272-275
146 www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors_(previously_Canagliflozin)/human_referral_prac_000059.jsp&mid=WC0b01ac05805c5
147 Neal B, Perkovic V, Mahaffey KW. et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657
148 Scheen AJ. Does lower limb amputation concern all SGLT2 inhibitors?. Nat Rev Endocrinol 2018; 14: 326-328
149 Fioretto P, Del Prato S, Buse JB. et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (CKD Stage 3 A): The DERIVE Study). Diabetes Obes Metab 2018; 20: 2532-2540
150 Inzucchi SE, Iliev H, Pfarr E. et al. Empagliflozin and assessment of lower limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 2018; 41: e4-e5
151 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306
152 Huang CY, Lee JK. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 Individuals. Diabetes Obes Metab 2020; 22: 2348-2355
153 Zhou Z, Jardine M, Perkovic V. et al. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia 2019; 62: 1854-1867
154 Perkovic V, Jardine MJ, Neal N. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295-2306
155 Mahaffey KW, Jardine MJ, Bompoint S. et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 2019; 140: 739-750
156 Kohler S, Kaspers S, Salsali A. et al. Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride. Diabetes Care 2018; 41: 1809-1816
157 Ruanpeng D, Ungprasert P, Sangtian J. et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes Metab Res Rev 2017; 33: e2903
158 Tang HL, Li DD, Zhang JJ. et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 2016; 18: 1199-1206
159 Li X, Li T, Cheng Y. et al. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis. Diabetes Metab Res Rev 2019; 35: e3170
160 Hidayat K, Du X, Shi BM. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodiumglucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporos Int 2019; 30: 1923-1940
161 Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017; 376: 2300-2303
162 Monami M, Nreu B, Zannoni S. et al. Effects of SGLT2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Res Clin Pract 2017; 130: 53-60
163 Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 2017; 60: 1385-1389
164 Liu J, Li L, Li S. et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020; 22: 1619-1627
165 Thiruvenkatarajan V, Meyer EJ, Nanjappa N. et al. Perioperative diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors: a systematic review. Br J Anaesth 2019; 123: 27-36
166 Milder DA, Milder TY, Kam PCA. Sodium-glucose co-transporter type-2 inhibitors: pharmacology and perioperative considerations. Anaesthesia 2018; 73: 1008-1018
167 Donnan K, Segar L. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol 2019; 846: 23-29
118 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357
169 Mosenzon O, Wiviott SD, Cahn A. et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 2019; 7: 606-617
170 Furtado RHM, Bonaca MP, Raz I. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and Previous Myocardial Infarction. Circulation 2019; 139: 2516-2527
171 Kato ET, Silverman MG, Mosenzon O. et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019; 139: 2528-2536
172 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995-2008
173 Wheeler DC, Stefánsson BV, Jongs N. et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 2021; 9: 22-31
174 Neuen BL, Young T, Heerspink HJL. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019; 7: 845-854
175 Karagiannis T, Tsapas A, Athanasiadou E. et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2021; 174: 108737
176 Bae JH, Park EG, Kim S. et al. Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Endocrinol Metab (Seoul) 2021; 36: 388-400
177 Palmer SC, Tendal B, Mustafa RA. et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021; 372: m4573
178 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
179 Inzucchi SE, Khunti K, Fitchett DH. et al. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. J Clin Endocrinol Metab 2020; 105: 3025-3035
180 McGuire DK, Zinman B, Inzucchi SE. et al. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary [99] Inzucchi SE, Iliev H, Pfarr E et al. Empagliflozin and assessment of lower limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 2018; 41: e4-e5
181 Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334
182 Cherney DZI, Zinman B, Inzucchi SE. et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebocontrolled trial. Lancet Diabetes Endocrinol 2017; 5: 610-621
183 Verma S, Mazer CD, Fitchett D. et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: sub-analysis of the EMPA-REG OUTCOME® randomized trial. Diabetologia 2018; 61: 1712-1723
184 Packer M, Anker SD, Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383: 1413-24
185 Zou CY, Liu XK, Sang YQ. et al. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes. A meta-analysis. Medicine (Baltimore) 2019; 98: e18245
186 Salah HM, Al’Aref SJ, Khan MS. et al. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. Am Heart J 2021; 233: 86-91
187 Qiu M, Ding L, Zhou H. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis. Medicine 2021; 100: e25121
188 Palmer SC, Tendal B, Mustafa RA. et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021; 372: m4573
189 Sattar N, McLaren J, Kristensen SL. et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia 2016; 59: 1333-1339
190 Ferrannini E, Mark M, Mayoux E. et al. CV Protection in the EMPA-REG OUTCOME Trial: A „thrifty substrate“ hypothesis. Diabetes Care 2016; 39: 1108-1114
191 Dutka M, Bobiński R, Ulman-Włodarz I. et al. Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure. Heart Failure Reviews 2021; 26: 603-622
192 Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 2018; 61: 2098-2107
193 Yurista SR, Chong CR, Badimon JJ. et al. Therapeutic Potenzial of Ketone Bodies for Patients With Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2021; 77: 1660-1669
194 https://www.gba.de/downloads/40–268–4342/2017–04–20_DMPARL_Aenderung-Anlage-1_DMP-Diabetes-mellitus_TrG.pdf
195 Cannon CP, McGuire DK, Pratley R. et al. VERTIS-CV Investigators. Design and baseline characteristics of the evaluation of ertugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J 2018; 206: 11-23
196 Cannon CP, Pratley R, Dagogo-Jack S. et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020; 383: 1425-1435
197 Rosenstock J, Frias J, Páll D. et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 2018; 20: 520-529
198 Hollander P, Liu J, Hill J. et al. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Diabetes Ther 2018; 9: 193-207
199 Cherney DZI, Heerspink HJL, Frederich R. et al. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia 2020; 63 1 128-1140
200 Cherney DZI, Charbonnel B, Cosentino F. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial; VERTIS CV Investigators. Diabetologia 2021; 64: 1256-1267
201 Marrs JC, Anderson SL. Ertugliflozin in the treatment of type 2 diabetes mellitus. Drugs in Context. 2020 9. 2020–7–4
202 Yu J, Li J, Leaver PJ. et al. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial. Cardiovasc Res 2021; 118: 1103-1114
203 Bhatt DL, Szarek M, Steg PG. et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med 2021; 384: 117-128
204 Bhatt DL, Szarek M, Pitt B. et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med 2021; 384: 129-139
205 Levin PA, Nguyen H, Wittbrodt ET. et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes 2017; 10: 123-139
206 Mac Isaac RJ. Dulaglutide and Insulin: How can the AWARD studies help guide clinical practice?. Diabetes Ther 2020; 11: 1627-1638
207 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a doubleblind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130
208 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomized, placebo-controlled trial. Lancet 2019; 394: 131-138
209 Dagenais GR, Rydén L, Leiter LA. et al. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol 2020; 19: 199
210 Lundgren JR, Janus C, Jensen SBK. et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med 2021; 384: 1719-1730
211 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322
212 Verma S, Bhatt DL, Bain SC. et al. Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease. Circulation 2018; 137: 2179-2183
213 Marso SP, Nauck MA, Monk Fries T. et al. Myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of liraglutide therapy (from the LEADER Trial). Am J Cardiol 2018; 121: 1467-1470
214 Duan CM, Wan TF, Wang Y. et al. Cardiovascular outcomes of liraglutide in patients with type 2 diabetes. A systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: 46 e17860
215 Mann JFE, Ørsted DD, Buse JB. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839-848
216 Kristensen SL, Rørth R, Jhund PS. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7: 776-785
217 Liu J, Li L, Deng K. et al. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 2017; 357: j2499
218 Pasternak B, Wintzell V, Eliasson B. et al. Use of glucagon like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care 2020; 43: 1326-1335
219 Mishriky BM, Cummings DM, Powell JR. et al. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 2019; 45: 102-109
220 Wilding JPH, Batterham RL, Calanna S. et al. STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384: 989
221 Wadden TA, Bailey TS, Billings LK. et al. STEP 3 Investigators Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on BodyWeight in AdultsWith Overweight or Original Article Obesity: The STEP 3 Randomized Clinical Trial. JAMA 2021; 325: 1403-1413
222 Rubino D, Abrahamsson N, Davies M. et al. STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021; 325: 1414-1425
223 Marso SP, Bain SC, Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844
224 Leiter LA, Bain SC, Hramiak I. et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol 2019; 18: 73
225 Husain M, Birkenfeld AL, Donsmark M. PIONEER 6 Investigators et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381: 841-851
226 Avgerinos I, Michailidis T, Liakos A. et al. Oral semaglutide for type 2 diabetes: A systematic review andmeta-analysis. Diabetes Obes Metab 2020; 22: 335-345
227 Husain M, Bain SC, Holst AG, Mark T, Rasmussen S, Lingvay I. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol 2020; 19: 156
228 Nauck MA, Quast DR. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Front Endocrinol (Lausanne) 2021; 12: 645 566
229 Zheng SL, Roddick AJ, Aghar-Jaffar R. et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagonlike peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA 2018; 319: 1580-1591
180 Dicembrini I, Nreu B, Scatena A. et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 2017; 54: 933-941
231 Mann JFE, Hansen T, Idorn T. et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol 2020; 8: 880-893
232 Home PD, Ahrén B, Reusch JEB. et al. Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Longterm efficacy with or without rescue therapy. Diabetes Res Clin Pract 2017; 131: 49-60
233 Ahrén B, Carr MC, Murphy K. et al. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. Diabetes Res Clin Pract 2017; 126: 230-239
234 Hernandez AF, Green JB, Janmohamed S. et al. Harmony outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebocontrolled trial. Lancet 2018; 392: 1519-1529
235 Rosenstock J, Nino A, Soffer J. et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020; 43: 2509-2518
236 Holman RR, Bethel MA, Mentz RJ. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228-1239
237 Fudim M, White J, Pagidipati NJ. et al. Effect of Once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure–related outcomes. Insights from the EXSCEL trial. Circulation 2019; 140: 1613-1622
238 Bonora BM, Avogaro A, Fadini GP. Effects of exenatide longacting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 2019; 56: 1051-1060
239 Jabbour SA, Frías JP, Ahmed A. et al. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes Care 2020; 43: 2528-2536
240 Bethel MA, Patel RA, Merrill P. et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 105-113
241 van der Aart - van der Beek AB, van Raalte DH, Guja C et al. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials. Diabetes Obes Metab 2020; 22: 1556–1566
242 Pfeffer MA, Claggett B, Diaz R. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247-57
243 Home P, Blonde L, Kalra S. et al. Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. Diabetes Obes Metab 2020; 22: 2179-2188
244 Gerstein HC, Sattar N, Rosenstock J. et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med 2021; 385: 896-907
245 Frias JP, Nauck MA, Van J, DO J. et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab 2020; 22: 938-946
246 Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol 2021; 9: 525-544
247 Rosenstock J, Wysham C, Frías JP. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomized, phase 3 trial. Lancet 2021; 398: 143-155
248 Frías JP, Davies MJ, Rosenstock J. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes; SURPASS-2 Investigators. N Engl J Med 2021; 385: 503-515
249 Hartman ML, Sanyal AJ, Loomba R. et al. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in PatientsWith Type 2 Diabetes. Diabetes Care 2020; 43: 1352-1355
250 Wilson JM, Nikooienejad A, Robins DA. et al. The dual glucosedependent insulinotropic peptide andglucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab 2020; 22: 2451-2459
251 Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther 2021; 12: 143-157
252 Vilsbøll T, Bain SC, Leiter LA. et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2018; 20: 889-897
253 Monami M, Nreu B, Scatena A. et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab 2017; 19: 1233-1241
254 Abd El Aziz M, Cahyadi O, Meier JJ. et al. Incretin-based glucoselowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab 2020; 22: 699-704
255 Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine 2019; 66: 157-165
256 Azoulay L, Filion KB, Platt RW. et al. Association between incretinbased drugs and the risk of acute pancreatitis. JAMA Intern Med 2016; 176: 1464-1473
257 Wang T, Wang F, Gou Z. et al. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1324 515 patients from observational studies. Diabetes Obes Metab 2015; 17: 32-41
258 Ueda P, Wintzell V, Melbye M. et al. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Diabetologia 2021; 64: 2204-2214
259 Piccoli GF, Mesquita LA, Stein C. et al. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis. J Clin Endocrinol Metab 2021; 106: 912-921
260 Newsome PN, Buchholtz K, Cusi K. et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021; 384: 1113-1124
261 Mantsiou C, Karagiannis T, Kakotrichi P. et al. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2020; 22: 1857-1868
262 Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab 2018; 20: 488-496
263 Landgraf R, Aberle J. Hundert Jahre – Insulin bleibt aktuell und notwendig. Diabetologie 2021; 16: 1-13
264 Marso SP, McGuire DK, Zinman B. et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. New Engl J Med 2017; 377: 723-732
265 Pieber TR, Marso SP, McGuire DK. et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 2018; 61: 58-65
266 Lau IT, Lee KF, So WY. et al. Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2017; 10: 273-284
267 Ritzel R, Roussel R, Giaccari A. et al. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab 2018; 20: 541-548
268 Bonadonna RC, Renard E, Cheng A. et al. Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?. Diabetes Res Clin Pract 2018; 142: 19-25
269 Linnebjerg H, Lam EC, Seger ME. et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963 016 insulin glargine and EU and US-approved versions of lantus insulin glargi ne in healthy subjects: Three randomized euglycemic clamp studies. Diabetes Care 2015; 38: 2226-2233
270 Rosenstock J, Hollander P, Bhargava A. et al. Similar efficacy and safety of LY2963 016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, doubleblind controlled trial (ELEMENT 2 study). Diabetes Obes Metabol 2015; 17: 734-741
271 Yamada T, Kamata R, Ishinohachi K. et al. Biosimilar vs originator insulins: Systematic review and meta-analysis. Diabetes Obes Metab 2018; 20: 1787-1792
272 But A, De Bruin ML, Bazelier MT. et al. Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia 2017; 60: 1691–1703 [222] Maiorino MI, Chiodini P, Bellastella G et al. Insulin and glucagon-like peptide1 receptor agonist combination therapy in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Care 2017; 40: 614-624
273 Guja C, Frías JP, Somogyi A. et al. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. Diabetes Obes Metab 2018; 20: 1602-1161
274 Rodbard HW, Lingvay I, Reed J. et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): A randomized, controlled trial. J Clin Endocrinol Metab 2018; 103: 2291-2301
275 Huthmacher JA, Meier JJ, Nauck MA. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Metaanalysis. Diabetes Care 2020; 43: 2303-2312
276 Gentile S, Fusco A, Colarusso S. et al. A randomized, openlabel, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin U-100 versus concentrated lispro insulin U-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence. Expert Opin Drug Saf 2018; 17: 445-450
277 Heise T, Hövelmann U, Brøndsted L. et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 2015; 17: 682-688
278 Bowering K, Case C, Harvey J. et al. Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: The ONSET 2 trial. Diabetes Care 2017; 40: 951-957
279 Leohr J, Dellva MA, Coutant DE. et al. Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in patients with type 2 diabetes mellitus: A phase I randomized, crossover study. Clin Pharmacokinet 2020; 59: 1601-1610
280 Preshaw PM, Alba AL, Herrera D. et al. Periodontitis and diabetes: a two-way relationship. Diabetologia 2012; 55: 21-31
281 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung, 1. Auflage. Version 4. 2013, zuletzt geändert: November 2014: www.dm-therapieversorgungsleitlinien.de S206